AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8446138 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 to 100 mg per day)
Number of subjects: 1292
Study 8446138 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (4 to 20 mg per day)
Number of subjects: 1292
Study 8446138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study 3535525 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel contact lenses with lower water content (38%)
Number of subjects: 10
Study 3535525 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel contact lenses with higher water content (55% and 70%)
Number of subjects: 10
Study 29898035 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional resistance training
Number of subjects: 50
Study 29898035 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resistance training
Number of subjects: 50
Study 29898035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 25792588 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel pad application
Number of subjects: 20
Study 25792588 — intervention group
Group type: COMPARATOR
Intervention: No gel pad application (control)
Number of subjects: 20
Study 24021313 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV 5555
Number of subjects: 260
Study 24021313 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV 5553
Number of subjects: 260
Study 24021313 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV 4444
Number of subjects: 260
Study 20056931 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA)
Number of subjects: 101
Study 20056931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 18633420 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor physical therapy (15 min daily, 5 times per week until discharge)
Number of subjects: 29
Study 18633420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 16849118 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dinner snack
Number of subjects: 60
Study 16849118 — intervention group
Group type: COMPARATOR
Intervention: No snack
Number of subjects: 60
Study 12770975 — intervention group
Group type: EXPERIMENTAL
Intervention: topical dorzolamide
Number of subjects: 36
Study 12770975 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 10971777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide anaesthesia
Number of subjects: 69
Study 10971777 — intervention group
Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 69
Study 9601864 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg or 6 mg
Number of subjects: 168
Study 9601864 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg (small proportion of patients)
Number of subjects: 168
Study 9601864 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril (overall treatment)
Number of subjects: 168
Study 8224265 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 500 mg/d
Number of subjects: 18
Study 8224265 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 750 mg/d
Number of subjects: 18
Study 8224265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8224265 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 500 mg/d and 750 mg/d
Number of subjects: 18
Study 3896278 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg three times daily
Number of subjects: 50
Study 3896278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29985636 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial pictorial warning labels (PWLs) with an image and basic warning statement
Number of subjects: 1255
Study 29985636 — intervention group
Group type: COMPARATOR
Intervention: Text only warning labels
Number of subjects: 1255
Study 29985636 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial PWLs with identifiers (name, age, health status)
Number of subjects: 1255
Study 29985636 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimonial PWLs with explanatory statements (testimonial/non-testimonial)
Number of subjects: 1255
Study 29985636 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic warning statement with an image of a real person
Number of subjects: 1255
Study 29120250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac treatment (0.1%, three times/day)
Number of subjects: 34
Study 29120250 — intervention group
Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 34
Study 26642810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg) combined with Capecitabine (2000 mg/m2 on days 1 to 14)
Number of subjects: 142
Study 26642810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg) combined with Vinorelbine (25 mg/m2 on days 1 and 8)
Number of subjects: 142
Study 26642810 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg) combined with Gemcitabine (1000 mg/m2 on days 1 and 8)
Number of subjects: 142
Study 24690511 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based self-management support programme (three monthly group sessions and a booster session three months later)
Number of subjects: 160
Study 24690511 — intervention group
Group type: COMPARATOR
Intervention: Single information meeting (control condition)
Number of subjects: 160
Study 23220811 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 39
Study 23220811 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulfate (1500 mg/day) plus exercise therapy
Number of subjects: 39
Study 20975470 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40
Study 20975470 — intervention group
Group type: COMPARATOR
Intervention: Landmark-based technique
Number of subjects: 40
Study 18591457 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (low-, medium-, or high-dose)
Number of subjects: 90
Study 18591457 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 90
Study 18591457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11295408 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g fosfomycin trometamol (single-dose)
Number of subjects: 100
Study 11295408 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ceftibuten (3-day course)
Number of subjects: 100
Study 9136253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 37
Study 9136253 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 37
Study 7970503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical, sequential combination of tamoxifen and megestrol acetate (group B)
Number of subjects: 261
Study 7970503 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (group A)
Number of subjects: 261
Study 3310318 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1.7 g/day)
Number of subjects: 18
Study 3310318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28273752 — intervention group
Group type: EXPERIMENTAL
Intervention: Codetalk, a simulation-based workshop
Number of subjects: 472
Study 28273752 — intervention group
Group type: COMPARATOR
Intervention: Usual education
Number of subjects: 472
Study 28787507 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 µg/kg/min for 24 hours)
Number of subjects: 336
Study 28787507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 28787507 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 336
Study 26978493 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐, L‐hopantenic acid (pantogam active) at a daily dose of 600 to 1200 mg for 28 days
Number of subjects: 80
Study 26978493 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiotropic hypotensive treatment (Control)
Number of subjects: 80
Study 24139424 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DR-DMF)
Number of subjects: 56
Study 24139424 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DR-DMF) with aspirin pretreatment
Number of subjects: 56
Study 24139424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 20878292 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss treatment
Number of subjects: 203
Study 20878292 — intervention group
Group type: COMPARATOR
Intervention: Behavioral weight loss combined with cognitive‐behavioral depression management
Number of subjects: 203
Study 18444133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants (dietary energy density reduction)
Number of subjects: 2718
Study 18444133 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 2718
Study 18444133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 2718
Study 17021318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg
Number of subjects: 716
Study 17021318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 716
Study 17021318 — intervention group
Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 716
Study 14618246 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPER‐HES (150 ml/m2 hypertonic NaCl (7.2%) 10% HES 200/0.5)
Number of subjects: 43
Study 14618246 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPER‐DEX (150 ml/m2 hypertonic NaCl (7.2%) 10% dextran 60)
Number of subjects: 43
Study 14618246 — intervention group
Group type: EXPERIMENTAL
Intervention: HES (250 ml/m2 10% HES 200/0.5 plus 400 ml/m2 NaCl 0.9%)
Number of subjects: 43
Study 14618246 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX (250 ml/m2 10% dextran 40 plus 300 ml/m2 NaCl 0.9%)
Number of subjects: 43
Study 14618246 — intervention group
Group type: COMPARATOR
Intervention: NACL (750 ml/m2 NaCl 0.9%)
Number of subjects: 43
Study 10763156 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 16 weeks of aerobic training at 75% to 85% of maximum capacity, three 1-hour bouts/week.
Number of subjects: 18
Study 10763156 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No exercise.
Number of subjects: 18
Study 8694323 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL bupivacaine 0.5% (Group 1)
Number of subjects: 30
Study 8694323 — intervention group
Group type: COMPARATOR
Intervention: 10 mL saline (Group 2)
Number of subjects: 30
Study 8694323 — intervention group
Group type: COMPARATOR
Intervention: No epidural top-up (Group 3)
Number of subjects: 30
Study 1562255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 0.7%
Number of subjects: 73
Study 1562255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 1.4%
Number of subjects: 73
Study 1562255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 73
Study 1562255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 31770235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment
Number of subjects: 828
Study 31770235 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D treatment
Number of subjects: 828
Study 31770235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (not receiving treatment)
Number of subjects: 828
Study 30304108 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 60
Study 30304108 — intervention group
Group type: COMPARATOR
Intervention: Alendronate + Curcumin
Number of subjects: 60
Study 30304108 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 27603001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy (intra- and extra-articular hypertonic dextrose injection)
Number of subjects: 22
Study 25132212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 12.5 mg once daily (n = 880)
Number of subjects: 2639
Study 25132212 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily (n = 885)
Number of subjects: 2639
Study 25132212 — intervention group
Group type: COMPARATOR
Intervention: Glipizide 5 mg once daily, titrated to a maximum of 20 mg (n = 874)
Number of subjects: 2639
Study 22243959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (mean 40.6 mg, SD 25 mg)
Number of subjects: 135
Study 22243959 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine alone (mean 14.4 mg, SD 9.4 mg)
Number of subjects: 135
Study 22243959 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of ketamine and morphine
Number of subjects: 135
Study 19858761 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (COMB) with risperidone and parent training (PT)
Number of subjects: 124
Study 19858761 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (MED)
Number of subjects: 124
Study 18281620 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel botulinum toxin A injections
Number of subjects: 46
Study 16168278 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 100 mg/day administered before bedtime
Number of subjects: 328
Study 16168278 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) 100 mg/day administered on awakening
Number of subjects: 328
Study 16168278 — intervention group
Group type: COMPARATOR
Intervention: Nonpharmacological hygienic-dietary recommendations
Number of subjects: 328
Study 12514662 — intervention group
Group type: EXPERIMENTAL
Intervention: TIMI 9B trial
Number of subjects: 3002
Study 12514662 — intervention group
Group type: COMPARATOR
Intervention: Not enrolled in TIMI 9B (Control)
Number of subjects: 3002
Study 12514662 — intervention group
Group type: COMPARATOR
Intervention: Ineligible patients not treated with reperfusion therapy (Control)
Number of subjects: 3002
Study 10536645 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of Alzheimer's patients
Number of subjects: 70
Study 10536645 — intervention group
Group type: EXPERIMENTAL
Intervention: Older women
Number of subjects: 70
Study 10536645 — intervention group
Group type: COMPARATOR
Intervention: Movers (older women assessed one month before relocation)
Number of subjects: 70
Study 10536645 — intervention group
Group type: EXPERIMENTAL
Intervention: All women
Number of subjects: 70
Study 8683232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate (EP) at 125 mg/m2/d for 5 days
Number of subjects: 29
Study 8683232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate (EP) at 150 mg/m2/d for 5 days
Number of subjects: 29
Study 8683232 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous etoposide (E) at 80 mg/m2 for 1 hour
Number of subjects: 29
Study 8683232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide phosphate (EP)
Number of subjects: 29
Study 2054272 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (repeated administration)
Number of subjects: 6
Study 2054272 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and Propranolol (co-administered as single doses)
Number of subjects: 6
Study 2054272 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (repeated doses)
Number of subjects: 6
Study 2054272 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and Propranolol (single and repeated oral doses in combination)
Number of subjects: 6
Study 2054272 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil and Propranolol (single doses in combination)
Number of subjects: 6
Study 6474840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 sec period of inspection of the grating or its fundamental preceding the test presentation
Number of subjects: 0
Study 6474840 — intervention group
Group type: EXPERIMENTAL
Intervention: Test presentation of gratings
Number of subjects: 0
Study 6474840 — intervention group
Group type: EXPERIMENTAL
Intervention: Low contrast and high frequency test presentations
Number of subjects: 0
Study 6474840 — intervention group
Group type: EXPERIMENTAL
Intervention: Real or simulated afterimages present during triangular-wave gratings
Number of subjects: 0
Study 6474840 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative afterimage effects eliminated
Number of subjects: 0
Study 31390454 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 32
Study 31390454 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Maxillary Expansion (SME)
Number of subjects: 32
Study 30716803 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-auricular subperiosteal injection of methylprednisolone combined with ginkgo biloba injection and mouse nerve growth factor
Number of subjects: 84
Study 30716803 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba injection and mouse nerve growth factor
Number of subjects: 84
Study 26486632 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Thoughts and Actions (PTA)
Number of subjects: 120
Study 26486632 — intervention group
Group type: COMPARATOR
Intervention: Individual Support Program (ISP)
Number of subjects: 120
Study 26486632 — intervention group
Group type: COMPARATOR
Intervention: Parent-reported internalizing symptoms and health behavior
Number of subjects: 120
Study 25245975 — intervention group
Group type: EXPERIMENTAL
Intervention: CGI
Number of subjects: 406
Study 25245975 — intervention group
Group type: EXPERIMENTAL
Intervention: IGT
Number of subjects: 406
Study 25245975 — intervention group
Group type: EXPERIMENTAL
Intervention: IFG
Number of subjects: 406
Study 25245975 — intervention group
Group type: EXPERIMENTAL
Intervention: elevated HbA1c
Number of subjects: 406
Study 25245975 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min postload glucose ≥ 165 mg/dL and 30-min C-peptide < 5 ng/mL
Number of subjects: 406
Study 22092097 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic simulation (n = 31)
Number of subjects: 64
Study 22092097 — intervention group
Group type: COMPARATOR
Intervention: Traditional test (n = 33)
Number of subjects: 64
Study 19464177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (250 mg/month)
Number of subjects: 14
Study 17513663 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia and analgesia
Number of subjects: 60
Study 17513663 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia followed by patient-controlled analgesia (control group)
Number of subjects: 60
Study 15204446 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching-learning programme using an interaction analysis system and video observation
Number of subjects: 36
Study 11590993 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine ethanol intake
Number of subjects: 437
Study 9852885 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus ICD implantation
Number of subjects: 900
Study 7537664 — intervention group
Group type: COMPARATOR
Intervention: Casodex 50 mg/day
Number of subjects: 3000
Study 7537664 — intervention group
Group type: COMPARATOR
Intervention: Casodex 150 mg/day
Number of subjects: 3000
Study 7537664 — intervention group
Group type: COMPARATOR
Intervention: Casodex 50 mg/day for prostate cancer
Number of subjects: 3000
Study 7537664 — intervention group
Group type: COMPARATOR
Intervention: Casodex 50 mg/day for benign prostatic hyperplasia (BPH)
Number of subjects: 3000
Study 7537664 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex (various doses)
Number of subjects: 3000
Study 2686666 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 30
Study 2686666 — intervention group
Group type: COMPARATOR
Intervention: Supervised outpatient physical therapy
Number of subjects: 30
Study 4392984 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol
Number of subjects: 24
Study 31820568 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized criteria combining triple hematologic parameters for NRBC
Number of subjects: 2491
Study 31820568 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized criteria combining triple hematologic parameters for AL
Number of subjects: 2491
Study 31820568 — intervention group
Group type: COMPARATOR
Intervention: Default setting for NRBC
Number of subjects: 2491
Study 31820568 — intervention group
Group type: COMPARATOR
Intervention: Default setting for AL
Number of subjects: 2491
Study 30314725 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy
Number of subjects: 120
Study 30314725 — intervention group
Group type: COMPARATOR
Intervention: 4-port laparoscopic cholecystectomy
Number of subjects: 120
Study 28463899 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing posture
Number of subjects: 18
Study 28463899 — intervention group
Group type: COMPARATOR
Intervention: Sitting posture
Number of subjects: 18
Study 25792076 — intervention group
Group type: EXPERIMENTAL
Intervention: M1-TMS
Number of subjects: 26
Study 25792076 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA-TMS
Number of subjects: 26
Study 25792076 — intervention group
Group type: COMPARATOR
Intervention: Cerebellar TMS
Number of subjects: 26
Study 25792076 — intervention group
Group type: EXPERIMENTAL
Intervention: M1-TMS in PD
Number of subjects: 26
Study 24187226 — intervention group
Group type: EXPERIMENTAL
Intervention: iPAM MkII system for assistive upper-limb exercise
Number of subjects: 0
Study 24187226 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21548943 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions focused on increasing physician familiarity with and motivation to follow guidelines.
Number of subjects: 156
Study 21548943 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving self-efficacy in performing guideline concordant care.
Number of subjects: 156
Study 18070967 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 600 mg BID
Number of subjects: 342
Study 18070967 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 800 mg BID
Number of subjects: 342
Study 18070967 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 200 mg BID
Number of subjects: 342
Study 18070967 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 400 mg BID
Number of subjects: 342
Study 18070967 — intervention group
Group type: EXPERIMENTAL
Intervention: APL 800 mg once a day
Number of subjects: 342
Study 18070967 — intervention group
Group type: COMPARATOR
Intervention: ZDV-3TC
Number of subjects: 342
Study 18070967 — intervention group
Group type: COMPARATOR
Intervention: EFV
Number of subjects: 342